Pharmacology, Toxicology and Pharmaceutical Science
Dolutegravir
100%
HIV
96%
Integrase
79%
Infection
44%
Human Immunodeficiency Virus 1 Infection
42%
Lamivudine
28%
Nonnucleoside Reverse Transcriptase Inhibitor
27%
Integrase Inhibitor
23%
Tenofovir Alafenamide
23%
Emtricitabine
23%
Bictegravir
22%
Human Immunodeficiency Virus 1
21%
Drug Resistance
20%
Investigational Drug
19%
Doravirine
19%
Aciclovir
19%
Cabotegravir
19%
Human Immunodeficiency Virus 2
19%
Tenofovir Disoproxil
14%
Neutralizing Antibody
7%
Antiretrovirus Agent
6%
Clinical Trial
6%
Immunology and Microbiology
Integrase
76%
Human Immunodeficiency Virus 1
61%
Human Immunodeficiency Virus
39%
Next Generation Sequencing
19%
Human Immunodeficiency Virus 2
19%
Viral Load
17%
Drug Resistance
16%
Virus
16%
DNA Binding
15%
Reverse Transcriptase
10%
Dideoxynucleotide Sequencing
7%
Rebound
7%
Immunodeficiency
6%
Capsid
6%
Long Terminal Repeat
5%
Medicine and Dentistry
Dolutegravir
38%
Infection
25%
Patient Compliance
19%
Human Immunodeficiency Virus
19%
HIV Drug Resistance
19%
Integrase
17%
Next Generation Sequencing
16%
Resistance Mutation
10%
Virus Capsid
7%
Rebound
7%
Virus
6%
Lamivudine
6%
Sanger Sequencing
6%